SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2018 / Cilt: 66 - Sayı: 1

In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates

Mycobacterium tuberculosis kökenleri üzerine siprofloksasin, levofloksasin ve moksifloksasinin in vitro etkinliği

Fethiye Ferda YILMAZ
Cengiz ÇAVUŞOĞLU
Mine HOŞGÖR LİMONCU
Bayrı ERAÇ
Şafak ERMERTCAN
Can BİÇMEN
Serir AKTOĞU ÖZKAN
Pages
32–36
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ciprofloxacin (CIP), levofloxacin (LEV) and moxifloxacin (MXF) susceptibilities were assessed by agar proportion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendations.Results: Twelve (15.2%), 5 (6.3%) and 4 (5.1%) of the MDR M. tuberculosis strains were resistant to CIP, LEV, MXF, respectively[resistance breakpoints (µg/mL); CIP (> 2), LEV (> 1), MXF (> 0.5)] while non-MDR strains were susceptible to CIP, LEV, MXF.Conclusion: Consequently, although high fluoroquinolone susceptibilities were evaluated as a pleasing data in this study, to preservetheir efficiency for many years steadily, quinolone usage and resistance increment in MDR M. tuberculosis isolates should be monitored elaborately.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In vitro effects of ciprofloxacin, levofloxacin and Moxifloxacin on Mycobacterium tuberculosis isolatesIntroduction: Increased tuberculosis prevalence, and isolation of multidrug resistant (MDR) Mycobacterium tuberculosis strains frequently as causative organisms from tuberculosis infections are resulted in increasing need of new anti-tuberculosis drugs.
📊
Key Findings & Data:It was aimed in this study to investigate phenotypically the fluoroquinolone susceptibility in MDR and non-MDR M. tuberculosis isolates.Materials and Methods: A total of 126 MDR and non-MDR M. tuberculosis isolates from mycobacteriology laboratory of two hospitals in the Aegean Region of Turkey were included in the study.
💡
Conclusion & Impact:Ciprofloxacin (CIP), levofloxacin (LEV) and moxifloxacin (MXF) susceptibilities were assessed by agar proportion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendations.Results: Twelve (15.2%), 5 (6.3%) and 4 (5.1%) of the MDR M. tuberculosis strains were resistant to CIP, LEV, MXF, respectively[resistance breakpoints (µg/mL); CIP (> 2), LEV (> 1), MXF (> 0.5)] while non-MDR strains were susceptible to CIP, LEV, MXF.Conclusion: Consequently, although high fluoroquinolone susceptibilities were evaluated as a pleasing data in this study, to preservetheir efficiency for many years steadily, quinolone usage and resistance increment in MDR M. tuberculosis isolates should be monitored elaborately.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In vitro effects of ciprofloxacin, levofloxacin and Moxifloxacin on Mycobacterium tuberculosis isolatesIntroduction: Increased tuberculosis prevalence, and isolation of multidrug resistant (MDR) Mycobacterium tuberculosis strains frequently as causative organisms from tuberculosis infections are resulted in increasing need of new anti-tuberculosis drugs. Nowadays,fluoroquinolones known to have fewer side effects than the other drugs used in treatment of tuberculosis are sometimes assessed evenas first-line anti-tuberculosis drugs due to their in vitro and in vivo strong activity. It was aimed in this study to investigate phenotypically the fluoroquinolone susceptibility in MDR and non-MDR M. tuberculosis isolates.Materials and Methods: A total of 126 MDR and non-MDR M. tuberculosis isolates from mycobacteriology laboratory of two hospitals in the Aegean Region of Turkey were included in the study. Ciprofloxacin (CIP), levofloxacin (LEV) and moxifloxacin (MXF) susceptibilities were assessed by agar proportion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendations.Results: Twelve (15.2%), 5 (6.3%) and 4 (5.1%) of the MDR M. tuberculosis strains were resistant to CIP, LEV, MXF, respectively[resistance breakpoints (µg/mL); CIP (> 2), LEV (> 1), MXF (> 0.5)] while non-MDR strains were susceptible to CIP, LEV, MXF.Conclusion: Consequently, although high fluoroquinolone susceptibilities were evaluated as a pleasing data in this study, to preservetheir efficiency for many years steadily, quinolone usage and resistance increment in MDR M. tuberculosis isolates should be monitored elaborately.

Özet

Giriş: Tüberküloz prevalansındaki artış ve çok ilaca dirençli (ÇİD) Mycobacterium tuberculosis suşlarının tüberküloz infeksiyonlarından sıklıkla etken organizmalar olarak izole edilmesi, yeni anti-tüberküloz ilaçlara duyulan ihtiyacın artmasına neden olmaktadır. Günümüzde, tüberküloz tedavisinde kullanılan ve diğer ilaçlardan daha az yan etkisi olduğu bilinen florokinolonlar, in vitro ve in vivo güçlü aktiviteleri nedeniyle bazen birinci basamak anti-tüberküloz ilaçlar olarak bile değerlendirilmektedir. Bu çalışmada, ÇİD ve ÇİD olmayan M. tuberculosis izolatlarında florokinolon duyarlılığının fenotipik olarak araştırılması amaçlanmıştır. Materyal ve Metod: Türkiye’de Ege Bölgesi’ndeki iki hastanenin mikobakteriyoloji laboratuvarından ÇİD ve ÇİD olmayan toplam 126 M. tuberculosis izolatı çalışmaya dahil edildi. Siprofloksasin (CIP), levofloksasin (LEV) ve moksifloksasin (MXF) duyarlılıkları, "Clinical and Laboratory Standards Institute (CLSI)" önerilerine göre agar proporsiyon yöntemi ile değerlendirildi. Bulgular: Çok ilaca dirençli M. tuberculosis izolatlarının 12 (%15.2)'si CIP, 5'i (%6.3) LEV ve 4 (%5.1)'ü MXF dirençliydi [direnç sınırları (μg/mL); CIP, LEV (> 1), MXF (> 0.5)]. Çok ilaca dirençli olmayan suşlar ise CIP, LEV, MXF’ye duyarlıydı. Sonuç: Yüksek florokinolon duyarlılıkları bu çalışma için memnuniyet verici bir veri olarak değerlendirilse de uzun yıllar florokinolonların etkinliğini korumak için kinolon kullanımı ve ÇİD M. tuberculosis izolatlarına karşı direnç artışı dikkatle izlenmelidir.

🔖

Cite This Article

YILMAZ, F. F., ÇAVUŞOĞLU, C., LİMONCU, M. H., ERAÇ, B., ERMERTCAN, Ş., BİÇMEN, C., ÖZKAN, S. A. (2022). In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates. Tüberküloz ve Toraks, Cilt: 66 - Sayı: 1, 32–36. https://ajindex.com/articles/618428

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Alışkan HE, Bostanoğlu E, Turunç T, Çolakoğlu Ş, Demiroğlu YZ, Kurşun E, et al. Retrospektif olarak tüberküloz laboratuvarının altı yıllık sonuçları ve antimikobakteriyel ilaçlara direnç oranları. Turk Toraks Derg 2013;14:53-8.
  2. Bozdağ İ, Coşar AD, Uysal EB, Özer A. Klinik örneklerden izole edilen Mycobacterium tuberculosis kompleks suşlarının antibiyotiklere direnç oranları. Tıp Araş Derg 2015;13(1):6-10.
  3. Cesur S, Şimşek H. Çoklu ilaca ve yaygın ilaca dirençli tüberküloz için hızlı tanı yöntemleri. Ortadoğu Med J 2015;7(2):85-90.
  4. Öz Y, Aslan M, Akşit F, Durmaz G, Kiraz N. Mycobacterium tuberculosis kompleks izolatlarının primer antitüberküloz ilaçlara duyarlılığının değerlendirilmesi. ANKEM Derg 2012;26(1):20-4.
  5. Uysal EB, Kaya H. Klinik örneklerden izole edilen Mycobacterium tuberculosis kompleks suşlarının major anti-tüberküloz ilaçlara duyarlılıkları. Tıp Araş Derg 2014;12(2):67-70.
  6. Eldin AS, Mostafa NM, Mostafa SI. Detection of fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates as determined by gyrA/B gene mutation by using PCR technique. Egyptian J Chest Dis Tub 2012;61:349-53. Özkara Ş. Yaygın ilaç dirençli tüberküloz (YİD-TB). Sol Hast 2007;18:88-92.
  7. Özkütük N, Sürücüğlu S, Gazi H, Coşkun M, Özkütük A, Özbakkaloğlu B. Second-line drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis isolates in Aegean Region-Turkey. Turk J Med Sci 2008;38(3):245-50.
  8. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Inf Disorders - Drug Targets 2007;7(2):159-68.
  9. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS ONE 2012;7(6):e39754. Mayer C, Takiff H. The molecular genetics of fluoroquinolone resistance in Mycobacterium tuberculosis. Microbiol Spectrum 2014;2(4):MGM2-0009-2013.
  10. Rubinstein E, Keynan Y. Quinolones for mycobacterial infections. Int J Antimic Agents 2013;42(1):1-4. Evranos-Aksöz B. Tüberküloz tedavisinde yeni ilaç adayları. Türk Hij Den Biyol Derg 2014;71(4):207-20.
  11. Kaya NM, Sarıbaş Z. Mikobakterilerde dışa atım pompaları ve ilaç direnci. Türk Mikrobiyol Cem Derg 2012;42(3):81- 4. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved standard-2nd ed. CLSI Document M24-A2. 2011,
  12. Wayne, PA. Perincek G, Tabakoğlu E, Otkun M, Özdemir L, Özdemir B. Mycobacter